July 2010

JACC: Integrilin as safe, effective as ReoPro in STEMI patients ()
NHS: Diabetes rise leads to overall healthcare cost increase in U.K. ()
Circ: 50% of acute MI patients develop hospital-acquired anemia during PCI ()
FDA committee looks to widen antiplatelet options with ticagrelor ()
Lillys income drops in Q2, again affected by healthcare reform ()
Edwards net income jumps $10M in Q2 on strong heart valves sales ()
Spectranetics skips into the black for Q2 ()
Feature: More cardiac patients seen, less Medicare reimbursement ()
Which antiplatelet drug is best for patients on PPIs? New trial to the rescue ()
CMS approves trial to evaluate warfarin responsivness ()
New heart transplant guidelines address gaps in care ()
Maquet launches new endoscopic vessel harvesting system ()
Lancet: IV alteplase for stroke safe after three hours ()
Circulation: Protocols slash delays, improve mortality for aortic dissection ()
First Word: Innovations that Zero-In on PCI Outcomes ()
Cath Lab Update: Hybrid Adoption & PCI Imaging Tools ()
Cardiologists Team with Other Specialists to Combat Sleep Apnea ()
Childrens Hospital of Philadelphia: Treating Single Ventricle Defects ()
ACC Corner: Medicare Payment, Health Reform Driving Need for Cardiology to Get Tough ()
News & Views ()
Health Affairs: Public hospital reporting needs to bulk up on data ()
In-House Marketing Specialist: Terrific Investment or Disastrous Mistake? ()
Cerenis scores $65M for R&D for HDL therapy ()
BMS income slips slightly, despite sales gains in Q2 ()
Bard looks good in Q2 ()
Level one vascular program reduces aortic emergency mortality ()
AIM: Surgery or stent for carotid artery disease? Depends on where you live ()
Circulation: Bivalirudin bests heparin in benefits, cost for high-risk PCI patients ()
Radiology: Mammo CAD, double reading each have advantages; neither infallible ()
Circulation: Most evidence-based strategies can IMPROVE HF ()
Nonprofit BCBS plans for surpluses, sought huge rate increases ()
Report: ER wait times rise; proper communication soothes dissatisfaction ()
JACC: Pre-hospital diagnosis, direct transport to PCI center reduce D2B times ()
NEJM: The Avandia chronicles, what to take from it ()
Harvard to initiate strict conflict of interest rules for faculty ()
Abbott posts slight Q2 gains, bolstered by 9% increase in stent sales ()
FDA halts TIDE trial, amid Avandia regulatory review ()
JACC: New guidelines outline proper HF, transplant care ()
Vasomedical releases iPhone app for EECP therapy ()
Lancet: HDL cholesterol in statin takers not predictive of CV risk ()
Accumetrics teams with Daiichi, Lilly for platelet function testing education ()
Double-digit gains for CV drugs propels Gilead's Q2 ()
AMDIS: Glaser calls for greater interoperability, accountability in gov't initiatives ()
Cardiac Sci predicts updated AED recall will cost up to $33.5M ()
J&J sees slight Q2 gains, while Cordis' sales slide ()
AAPM: C-arm radiation scatter least at head & feet ()
EJHF: Bronchodilators are independent risk factor of worsening HF ()
Diabetes societies urge patients on Avandia to stay the course ()
Circulation: Exercise training for HF patients shifts costs to patients ()
N.Y. audit reveals public AEDs in need of better oversight ()
Louisiana town outfits police vehicles with AEDs ()
JACC: 'Wearable' ICDs prevent sudden death ()
Glaser Video: What CMIOs and CIOs should be discussing now ()
Olympic AEDs given to community ()
First time AED Plus used on large cruise liner ()
AngioDynamics posts solid Q4 & FY10 growth ()
HHS to require payors to cover CV-related preventive screenings ()
As Avandia regulatory fate looms, firm predicts sales drop ()
Novartis posts strong Q2, CV unit comes up big ()
Survey: Salary growth for C-suite health execs slows, but retention is up ()
Takeda defends Actos, in light of FDA committee meeting ()
GSK reportedly settles 10,000 Avandia liability claims for $460M ()
Bos Sci launches MultiSENSE trial to test CRT-D monitoring ()
TriVascular nets $60M in financing ()
National Cardio Labs settles whistleblower suit for $3.6M ()
JAMA: Most physicians don't report incompetent colleagues ()
Cardiac Science introduces new diagnostic workstation ()
FDA committee may decide fate of Avandia ()
J&J to buy Micrus Endovascular for deal valued at $480M ()
AngioDynamics expands power-injectable port line ()
ev3 settles class action suits over Covidien takeover ()
BMS recalls Coumadin lots ()
Ethicon expands hemostasis portfolio ()
Merck to shut down 16 sites, shed 15% of employees ()
Circulation: Sleep apnea in men boosts risk of HF, heart disease ()
Health Affairs: Patient-physician email improves diabetes, hypertension care ()
Health Affairs: Modifying generic med substitution laws could slash almost $100M ()
Study: Telephone-based diabetes management could save $3M ()
Report Sanofi-Aventis may be looking to ink $20B pharma deal ()
JACC: Ticagrelor doesn't decrease cardiac, pulmonary function ()
Report: A-fib drugs to reach nearly $7B by 2019, with Multaq earning $650M ()
Circulation: Endo repair for aortic aneurysms holds promise, problems ()
JAMA: Aggressive BP goals may be risky for diabetics with CAD ()
AIM: Statins fail test to reduce all-cause mortality ()
AJR: 3D MR technique shows promise for pelvic imaging in women ()
Cambridge Heart launches T-Wave alternans trial ()
PLoS: Pay-for-performance could hurt those in less-advantaged areas ()
HRJ: Women may require unique ICD implantation considerations ()
JACC: Sprint Fidelis leads are successfully extracted at high-volume facilities ()
Physio-Control issues recall of Lifepak 20, Lifepak 20e ()
AHA selects Boston card as phyisician of the year ()
AJR: Training and testing boost rads CTC performance ()
ADA: Avandia doesn't increse death, MI, BARI 2D finds ()
AIM: Avandia leads to increased risk of MI, meta-analysis finds ()
JACC: Simple assay test identifies clopidogrel low responders ()